Sarcomas and DDR-Inhibition; a Combined Modality Study

NCT ID: NCT05116254

Last Updated: 2026-01-23

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-18
• Study Completion Date: 2025-12-09

Brief Summary

To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality treatment (CMT) by administering AZD1390 with or without durvalumab and RT concurrently treating newly diagnosed, non-metastatic soft tissue sarcoma patients with DDRi-based CMT, in the specific context of systemic toxicities, wound healing post-surgery and in defining the RP2D for the combinations to support further clinical evaluation.

Detailed Description

Despite improvements in surgery and radiation for soft tissue sarcoma (STS) patients, local relapses remain an important event for these patients. Most STS subtypes are considered radioresistant and immune cold tumor due to a lack of T-cell infiltration. Investigations into radiosensitization mediated by combining systemic compounds with neoadjuvant radiotherapy (RT) may translate into an increased rate of pathological responses, an increased rate of R0 resections and thus fewer local relapses.

RT is highly potent in inducing DNA damage. Normal cells are usually sufficiently able to repair this damage timely before the next fraction because of an intact DNA Damage Response (DDR) pathway. Frequently, tumor cells have (partial or complete) defects in the DDR pathways rendering them more sensitive to radiation than normal tissues. Inhibition of constituents of the DDR pathways may further widen the therapeutic window of fractionated radiotherapy, and combined with radiotherapy may result in increased tumor T-cell infiltration, creating an opportunity for immunotherapy. Clinical studies into radiosensitization of STS by combinations of radiotherapy and DDR inhibitors with or without immunotherapy are warranted. In this study the DDR candidate inhibitor is new drug candidate AZD1390 targeting ATM (Ataxia Telangiectasia Mutated). The immunotherapy candidate of this study is durvalumab (MEDI4736) targeting PD-L1 (programmed death-ligand 1).

Conditions

Soft Tissue Sarcoma Adult

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AZD1390

The experimental oral drug AZD1390 (starting dose once daily 20 mg) will be combined with radiotherapy. Drug will be taken at same day as radiotherapy for 5 weeks at weekdays.

When starting dose of 20 mg is proven safe the next cohort will be 100 and thereafter 200, 400 mg

Group Type: OTHER

AZD1390 + radiotherapy

Intervention Type: COMBINATION_PRODUCT

AZD1390 combined with preoperative radiotherapy

AZD1390 + durvalumab

The experimental oral drug AZD1390 (starting dose once daily 20 mg) will be combined with radiotherapy and durvalumab (fixed dose 1500 mg Q4W, until surgery). Drug will be taken at same day as radiotherapy for 5 weeks at weekdays. The dose of AZD1390 in the AZD1390 plus durvalumab cohort will follow the dosing of the AZD1390 only cohort. When starting dose of 20 mg and the next dose of AZD1390 only has been proven safe, the next cohort will be 100 and thereafter 200, 400 mg.

Group Type: OTHER

AZD1390 + durvlaumab + radiotherapy

Intervention Type: COMBINATION_PRODUCT

AZD1390 combined with durvalumab and preoperative radiotherapy

Interventions

AZD1390 + radiotherapy

AZD1390 combined with preoperative radiotherapy

Intervention Type: COMBINATION_PRODUCT

AZD1390 + durvlaumab + radiotherapy

AZD1390 combined with durvalumab and preoperative radiotherapy

Intervention Type: COMBINATION_PRODUCT

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, for which the standard treatment is a combination of RT and surgery (in other words deep seated and/or > 5cm in largest tumor diameter and/or an anticipated close resection margin and/or grade II/III according to the FNCLCC definition);
• Patients staged by at least a CT scan of the chest (and a CT scan of the abdomen, if deemed indicated according to local practices, e.g. in case of a myxoid liposarcoma). Staging may also be performed by FDG-PET scanning and or total body MRI scans. This staging procedure should not reveal metastatic disease. If, however, a low metastatic burden is detected such that this does not preclude the application of both preoperative RT and definitive surgery, patients are allowed to participate;
• WHO Performance Status ≤ 2;
• Able and willing to undergo preoperative RT;
• Able and willing to undergo definitive surgery;
• Able and willing to comply with regular follow-up visits;
• Able and willing to swallow and retain oral medication;
• Age ≥ 18 years;
• Body weight >30kg;
• Must have a life expectancy of at least 12 weeks;
• Adequate organ function as defined in Table 5;
• Signed written informed consent prior to any study specific procedures or sampling

Exclusion Criteria

• Patients with any type soft tissue sarcoma located above the clavicles.
• Prior malignancies; except another malignancy and disease-free for ≥ 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma;
• Patients with recurrent sarcomas who underwent prior RT to the target lesion (if the primary sarcoma was managed by surgery only and no perioperative RT, patients are eligible);
• Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), bone sarcomas;
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
• Female patients who are pregnant or breast feeding;
• Intention to perform an isolated limb perfusion, instead of a tumor resection;
• Neoadjuvant chemotherapy to be scheduled between end of RT and definitive surgery is not allowed. (neoadjuvant chemotherapy before start of study RT is allowed);
• Concomitant treatment with medicines listed as 'prohibited' or 'excluded';
• Treatment with moderate and strong inhibitors or inducers of CYP3A4 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort);

Additional criteria for durvalumab plus AZD1390:

• Past medical history of allogenic organ transplantation;
• Past medical history of leptomeningeal carcinomatosis;
• Past medical history or active autoimmune or inflammatory disorders
• History or presence of primary immunodeficiency
• Presence of active hepatitis infections or HIV
• Treatment with or prior use of immunosuppressive medication within 2 weeks before the start of treatment
• Prior treatment with anti-PD-1, anti PD-L1 or anti CTLA-4 immunotherapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Leiden University Medical Center

OTHER

Sponsor Role: collaborator

University Medical Center Nijmegen

OTHER

Sponsor Role: collaborator

The Netherlands Cancer Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rick Haas, MD Prof

Role: PRINCIPAL_INVESTIGATOR

The Netherlands Cancer Institute

Locations

Antoni van Leeuwenhoek

Amsterdam, , Netherlands

Countries

Netherlands

Other Identifiers

M21SAD

Identifier Type: -

Identifier Source: org_study_id